Clinical trial
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
NCT00002753 · Duke University, Other · Completed
Key facts
| NCT number | NCT00002753 |
|---|---|
| Title | Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas |
| Official title | PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS |
| Lead sponsor | Duke University, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Radiation |
| Interventions | iodine I 131 monoclonal antibody 81C6 |
| Enrollment | 6 |
| Start date | Nov 1, 1991 |
| Primary completion | Apr 1, 2001 |
| Completion | Apr 1, 2001 |
| First posted | Jul 29, 2004 |
| Last update posted | Feb 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: